>And from a societal point of view will divert a lot of cash that payors shell out for high-priced biologics into less productive channels than currently is the case.<
You are not seriously using [the need for] economic rationalism in US healthcare to defend Genentech are you? They are the poster child for the unsustainable cost vs. benefit system the country finds itself in.
Market Data 
Markets 
AI
